Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

644

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

September 30, 2009

Conditions
Major Depressive Disorder
Interventions
DRUG

agomelatine

DRUG

placebo

Trial Locations (78)

10021

Novartis Investigative Site, New York

10029

Novartis Investigative Site, New York

10467

Novartis Investigative Site, The Bronx

14215

Novartis Investigative Site, Buffalo

15213

Novartis Investigative Site, Pittsburgh

15238

Novartis Investigative Site, Pittsburgh

18104

Novartis Investigative Site, Allentown

19139

Novartis Investigative Site, Philadelphia

19446

Novartis Investigative Site, Lansdale

20852

Novartis Investigative Site, Rockville

21204

Novartis Investigative Site, Towson

23230

Novartis Investigative Site, Richmond

Novartis Investigative Site, Virginia Beach

27599

Novartis Investigative Site, Chapel Hill

27609

Novartis Investigative Site, Raleigh

29412

Novartis Investigative Site, Charleston

30328

Novartis Investigative Site, Atlanta

32216

Novartis Investigative Site, Jacksonville

32607

Novartis Investigative Site, Gainesville

33065

Novartis Investigative Site, Coral Springs

33407

Novartis Investigative Site, West Palm Beach

33702

Novartis Investigative Site, St. Petersburg

33912

Novartis Investigative Site, Fort Myers

34208

Novartis Investigative Site, Bradenton

34285

Novartis Investigative Site, Venice

35226

Novartis Investigative Site, Birmingham

37212

Novartis Investigative Site, Nashville

38119

Novartis Investigative Site, Memphis

43210

Novartis Investigative Site, Columbus

43623

Novartis Investigative Site, Toledo

44195

Novartis Investigative Site, Cleveland

48336

Novartis Investigative Site, Farmington Hills

53226

Novartis Investigative Site, Milwaukee

53227

Novartis Investigative Site, West Allis

55454

Novartis Investigative Site, Minneapolis

60048

Novartis Investigative Site, Libertyville

60611

Novartis Investigative Site, Chicago

60640

Novartis Investigative Site, Chicago

63033

Novartis Investigative Site, St Louis

63044

Novartis Investigative Site, St Louis

63118

Novartis Investigative Site, St Louis

64111

Novartis Investigative Site, Kansas City

66160

Novartis Investigative Site, Kansas City

66211

Novartis Investigative Site, Overland Park

66606

Novartis Investigative Site, Topeka

68198

Novartis Investigative Site, Omaha

70114

Novartis Investigative Site, New Orleans

75115

Novartis Investigative Site, DeSoto

77007

Novartis Investigative Site, Houston

77030

Novartis Investigative Site, Houston

77042

Novartis Investigative Site, Houston

77566

Novartis Investigative Site, Lake Jackson

78754

Novartis Investigative Site, Austin

78756

Novartis Investigative Site, Austin

80033

Novartis Investigative Site, Wheat Ridge

85381

Novartis Investigative Site, Peoria

85724

Novartis Investigative Site, Tucson

Novartis Investigative Site, Towson

87102

Novartis Investigative Site, Albuquerque

90024

Novartis Investigative Site, Los Angeles

90210

Novartis Investigative Site, Beverly Hills

91206

Novartis Investigative Site, Glendale

91316

Novartis Investigative Site, Encino

91403

Novartis Investigative Site, Sherman Oaks

92056

Novartis Investigative Site, Oceanside

92591

Novartis Investigative Site, Temecula

92626

Novartis Investigative Site, Costa Mesa

92660

Novartis Investigative Site, Newport Beach

95817

Novartis Investigative Site, Sacramento

97049

Novartis Investigative Site, Rhododendron

97210

Novartis Investigative Site, Portland

97239

Novartis Investigative Site, Portland

98026

Novartis Investigative Site, Edmonds

98104

Novartis Investigative Site, Seattle

02135

Novartis Investigative Site, Boston

02184

Novartis Investigative Site, Braintree

01605

Novartis Investigative Site, Worcester

07103

Novartis Investigative Site, Newark

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00467402 - Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder | Biotech Hunter | Biotech Hunter